Vantictumab, formerly identified as OMP18R5, represents an novel monoclonal antibody designed for specifically inhibit OPN protein 18R5. The therapy is being evaluated by Amgen in possible uses in several bone disorders, particularly those involving increased skeleton loss. Preclinical data suggest it may efficiently lower bone cell process, leadin